GCVI Summit 2018
Skip Content

3 July 2017

Zipkin flies out of Takeda

Takeda Ventures senior investment director Ilan Zipkin has become the second high-profile departure from the unit in four months to join the Parker Institute for Cancer Immunotherapy.

Author: James Mawson, Editor-in-chief

Ilan Zipkin, senior investment director at Takeda Ventures, Japan-based pharmaceutical company Takeda's corporate venturing unit, has left after five years to become vice-president of business development at the Parker Institute for Cancer Immunotherapy.